Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pip Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 39

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pip Review, H2 2018

Summary

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 7 and 4 respectively.

Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Hematological Tumor, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Chondrosarcoma, Glioblastoma Multiforme (GBM), Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer and Pancreatic Cancer.

The latest report Myc Proto Oncogene Protein - Pip Review, H2 2018, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

- The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects

- The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pip Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Overview
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development
Peptomyc SL
Phylogica Ltd
Sorrento Therapeutics Inc
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Drug Profiles
BGA-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-4000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galarmin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit c-Myc for Solid Tumors and Hematological Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit cMyc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Peptomyc SL, H2 2018
Pipeline by Phylogica Ltd, H2 2018
Pipeline by Sorrento Therapeutics Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Myelodysplastic Syndrome Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 128
    Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.[2] Early on there are typically no symptoms.Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent infections.[2] Some types may develop into acute myeloid leukemia. The presence of diagnostic tools is the key driver for the growth of this market. Diagnosis techniques like blood count, peri......
  • Global Myasthenia Gravis Drugs Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 120
    Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market's growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal ......
  • Global MRSA Drugs Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 122
    Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. The infection causes skin and tissue infection, and is transmitted by direct skin-to-skin contact......
  • Global Fibrin Sealants Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 125
    Fibrin sealant, a two-component substance consisting of thrombin and fibrinogen, is used as a hemostatic or adhesive in various surgical solutions. In clinical practice, a fibrin sealant consists of a concentrated solution of fibrinogen and Factor XIII, which combine with a solution of calcium and thrombin to form a coagulum that stimulates clotting. Beriplast P and TISSEEL are some of the commercially available fibrin sealants. The Americas accounted for 48% of the market share during th......
  • Global Female Contraceptive Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 110
    Female contraceptives, also known as female birth control are methods of preventing pregnancy that primarily involve the female physiology. Female contraceptive devices account for major shares of the contraceptive pills market throughout the forecast period. The increasing adoption of female contraceptive devices will drive the growth of this product segment in the female contraceptive market. The Americas will be the major revenue contributor to the contraceptive pills market thr......
  • Global Female Condoms Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 114
    A female condom is a birth control device that acts as a barrier to prevent sexual fluids from entering the vagina during intercourse. It protects against pregnancy and sexually transmitted infections (STIs). The online stores will be the fastest-growing segment and will continue to maintain its lead in the global market. Much of the segment's growth is due to its higher penetration rate and adoptability. Female condoms are easily accessible online and allow for useful comparison in terms......
  • Global Excipients Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 111
    Excipients are inert substances that are generally used to manufacture different forms of drugs and are present in the finished products. Excipients help in providing long-term stability and make solid formulations bulkier. They also improve the functionality of drugs and make them safer. Based on functionality, the pharmaceutical excipients market is segmented into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disint......
  • Global Consumer Healthcare Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 127
    Consumer healthcare products include trusted brands of multivitamins and iron supplements, in addition to products for allergies, personal hygiene, sleep support, alertness and cold and flu. Consumer health products do not require a written prescription from healthcare professionals but can be purchased directly from a pharmacy store. The global Consumer Healthcare market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx%......
  • Global Intravenous (IV) Ibuprofen Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 114
    Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The global Intravenous (IV) Ibuprofen market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Intravenous (IV) Ibuprofen ma......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs